GSK submits melanoma drug combo for FDA approval

07/10/2013 | Reuters

GlaxoSmithKline filed an application with the FDA for approval to market a combination of dabrafenib and trametinib as a treatment for melanoma. The application is supported by data from a Phase I/II trial. Dabrafenib and trametinib, sold under the brand names Tafinlar and Mekinist, respectively, were individually approved by the FDA in May.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC